Adma Biologics Inc
ADMA Biologics: Wall Street Projects Robust Revenue Growth
ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest Pharmaceuticals Corporation.
Why ADMA Biologics Stock Soared Yesterday
Yesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price.